“Through our partnership with Trevia, the innovative and new neuropathy screening solution from Prosenex provides temperature and vibratory testing for peripheral neuropathy assessments,” Dr. Boris Golosarsky, Chief Medical Officer for Prosenex said.
OVERLAND PARK, KS (PRWEB) November 16, 2015
TreVia Digital Health LLC (TreVia), innovators in cutting-edge technology-enabled services and solutions for the diabetes care industry, and Prosenex, a pioneering device company that specializes in medical objective screening for peripheral neuropathy, announced today an exclusive strategic partnership in which TreVia will integrate the Prosenex Dynamic Neuroscreening Device (DND) to create a new standard of care for screening of neuropathy and loss of protective sensation (LOPS).
“The scale of the diabetes chronic disease epidemic in this country is staggering. It demands innovative, scalable models for early detection using objective data to proactively and objectively baseline and chronicle progression," Maureen Peszko, Trevia’s President stated. "This is about preventing limb loss and helping millions of Americans maintain a quality lifestyle – especially for those at risk for diabetic complications. A recent study in the Journal of the American Medical Association demonstrated that chronic disease accounts for 84 percent of U.S. health care costs; making accessibility of this innovative and simple diagnostics tool not only a clinical imperative, but an economic one. TreVia enables neuropathy screening using the portable Prosenex device and delivering lifetime progression evaluation data for patients where and when they need it most. Studies suggest that by performing neuropathy evaluations during each physician or home care visit, providers are uniquely equipped to promote lifestyle changes, deliver preventative care and affect clinical symptoms sooner – ultimately preserving a better quality of life, avoiding limb loss and creating improved health care economics.”
“Through our partnership with Trevia, the innovative and new neuropathy screening solution from Prosenex provides temperature and vibratory testing for peripheral neuropathy assessments,” Dr. Boris Golosarsky, Chief Medical Officer for Prosenex said. “Through Trevia’s SmartCare experience, the results are captured and stored for immediate evaluation, as well as for longitudinal evaluation and progression measures within the EHR,” stated Golosarsky.
The Prosenex DND provides demonstrable, objective documentation to support the new American Diabetes Association standard of care, which suggests a foot screening at every appointment to measure progression and identify neurological issues to avoid limb loss.
The ability to objectively determine and record patients’ abilities to discern temperature and vibration will provide physicians with objective data that can be more effectively scrutinized. According to Golosarsky, objectivity will allow physicians to achieve a more thorough understanding of the stage of any given patient’s neuropathy, thereby allowing them to provide the most effective and timely treatment for improved patient outcomes. The DND was conceived by a physician out of necessity of daily medical practice, when devastating clinical presentation of neuropathy, especially painless, is often missed. Further, the conversion to electronic patient record keeping will make it easier to compare patients at different stages of their disease as well as from one patient to another.
The CDC estimates that 86 million American adults are currently living with prediabetes – an 8 percent increase in the past decade – while describing chronic disease as “the public health challenge of our generation.” In 2012, type 2 diabetes cost the United States over $245 billion in medical costs and lost productivity. TreVia is the first to partner on a digital neuropathy program to add more preventative care and data as part of a diabetes prevention program to combat this growing epidemic.
“TreVia is excited about the partnership with Prosenex as it provides a disruptive technological leap in neuropathy management and diabetes care that is uniquely integrated with the TreVia software platform to deliver enhanced services, improved quality and elevated standard of peripheral neuropathy care,” added Peszko. “It is our mission to provide better patient outcomes by advancing a new level of digital collaboration that enables us to detect issues early, reduce potential limb loss, and lower healthcare costs overall.”
About TreVia Digital Health
TreVia Digital Health provides an innovative, holistic and conveniently accessible diabetes care experience that uses technology-enabled services, including digital diabetes screenings using telemedicine, for the prevention of chronic and polychronic diabetic complications. TreVia measurably impacts diabetes outcomes by identifying issues early, using technology to connect the best specialists for virtual evaluation and treatment while preventing complications, resulting in an improved patient experience and overall lower health care costs.
Today, TreVia provides diabetes screening, including retinopathy and peripheral neuropathy, glucose monitoring and mapping, and affective computing for patient engagement including interval learning, behavior evaluation and lifestyle coaching for those affected by diabetes and pre-diabetes conditions. For more information about Trevia Digital Health, LLC., please visit http://www.treviadigitalhealth.com.
Prosenex specializes in medical objective screening for peripheral neuropathy across multiple medical specialties. The company’s current portfolio of medical products and product designs is focused on addressing the unmet market needs of primary care physicians, podiatrists, neurologists, endocrinologists and occupational therapists in the screening of patients for peripheral neuropathy due to diabetes and other causes.
For TreVia Digital Health